Skip to main content

MorphoSys and GeneFrontier Pen Marketing Collaboration

NEW YORK, Sept. 24 (GenomeWeb News) - MorphoSys of Munich and GeneFrontier of Tokyo will co-market MorphoSys' human antibody technology in Japan, the companies said yesterday.

 

Under the multi-year agreement, the two companies will market MorphoSys' Human Combinatorial Antibody Library technology in Japanfor both research and therapeutic applications. The deal is part of MorphoSys' effort to expand into new geographic markets.

 

As part of an ongoing pre-marketing agreement, MorphoSys and GeneFrontier have already conducted several research projects with Japanese partners.

The Scan

Possibly as Transmissible

Officials in the UK say the B.1.617.2 variant of SARS-CoV-2 may be as transmitted as easily as the B.1.1.7 variant that was identified in the UK, New Scientist reports.

Gene Therapy for SCID 'Encouraging'

The Associated Press reports that a gene therapy appears to be effective in treating severe combined immunodeficiency syndrome.

To Watch the Variants

Scientists told US lawmakers that SARS-CoV-2 variants need to be better monitored, the New York Times reports.

Nature Papers Present Nautilus Genome, Tool to Analyze Single-Cell Data, More

In Nature this week: nautilus genome gives peek into its evolution, computational tool to analyze single-cell ATAC-seq data, and more.